Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + SOX Neoadjuvant for Advanced Gastric/GEJ Cancer
NCT04890392Phase 2Unknown
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04890392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890392.